Business Wire

Agendia’s MammaPrint ® Test is the First to Demonstrate the Ability to Predict Benefit from Extended Endocrine Treatment in NSABP B-42 Trial

Share

Agendia, Inc., a world leader in precision oncology for breast cancer, today announced positive results from an analysis using its 70-gene MammaPrint® assay on samples from the NSABP B-42 trial. These results were reported as an oral presentation at the 2021 American Society of Clinical Oncology (ASCO) Annual Meeting.

The abstract, titled “Utility of the 70-gene MammaPrint assay for prediction of benefit from extended letrozole therapy (ELT) in the NRG Oncology/NSABP B-42 trial” and presented by Dr. Priya Rastogi of the NSABP, detailed a retrospective evaluation of 1,866 samples, almost half of the original trial’s tissue samples, which were representative of the entire cohort. The data showed that genomic testing with MammaPrint could identify a subset of patients in the NSABP B-42 cohort who were most likely to benefit from ELT. Patients with a MammaPrint Low Risk profile had significantly better rates of distant recurrence (DR), disease-free survival (DFS) and breast cancer free interval (BCFI) when treated with extended endocrine therapy. Conversely, genomically High Risk patients did not see this same benefit and likely could have been spared extended endocrine therapy.

Patients with a genomic Low Risk result were stratified into Ultra Low Risk and Low Risk groups. The benefit of extended endocrine therapy was primarily observed in the Low Risk (non-Ultra Low) group. The benefit of extended endocrine therapy in these MammaPrint Low Risk patients ranged from a 4.0% improvement in DR rate to a 9.5% increase in DFS. MammaPrint was the only test that predicted a 52% relative benefit reduction in BCFI events (7.9% absolute benefit) and a 36% relative benefit reduction in DFS events (9.5% absolute benefit) with ELT. Another genomic test, the BCI-H/I ratio, evaluated samples from the NSABP B-42 trial and did not confirm the predictive value of BCI for the efficacy of extended endocrine therapy; further study is needed to evaluate the test’s predictive ability.

“By stratifying patients beyond High or Low Risk, we are able to see a larger breadth of difference in genomic signatures,” said Adam Brufsky, MD, PhD, Co-Director of the Women’s Cancer Center at Magee Women’s Hospital of UPMC Hillman Cancer Center. “More granular information such as this allows us to better understand the biology of a tumor, and gets us closer to ensuring that each patient receives the data she needs to have informed discussions with her physician to decide on the best treatment path, even years after her initial treatment.”

The original NSABP B-42 trial, designed to determine whether ELT improves DFS after a standard 5 years of aromatase inhibitor-based therapy, enrolled nearly 4,000 postmenopausal women with stage I-IIIA hormone receptor-positive breast cancer, who were disease-free after about 5 years of treatment with an aromatase inhibitor or tamoxifen followed by an aromatase inhibitor. The trial arms were randomly assigned to either receive 5 years of letrozole – an endocrine therapy used commonly in adjuvant settings – or a placebo. The trial showed a numerical DFS benefit of 3.3% at 10 years from ELT for the entire study cohort; however, no clinical features that indicated which women would achieve this benefit were identified in the trial. This led to the search for genomic biomarkers which could predict the benefit of ELT, and was the basis for this translational study.

“We are pleased to have contributed to the NSABP B-42 trial findings, with the important observation that genomic profiling with MammaPrint identifies the cohort most likely to benefit from ELT, and those who are unlikely to benefit,” said William Audeh, MD, Chief Medical Officer at Agendia. “These data will be of value to clinicians, and women with breast cancer, as they make the challenging decision as to whether to undertake an additional five years of endocrine therapy, a decision for which clinical features offered little guidance.”

At ASCO 2021, Agendia also presented additional data about the Ultra Low Risk threshold from the MINDACT study as well as a larger suite of data from the company’s groundbreaking FLEX registry, a large-scale, prospective, observational breast cancer study using whole transcriptome sequencing. FLEX enables true precision oncology by recruiting patients from various ethnicities, ages and genders representative of the total breast cancer population as part of an ongoing effort to increase representation of diverse populations and data in clinical trials.

About Agendia

Agendia is a precision oncology company headquartered in Irvine, California, committed to bringing patients with early stage breast cancer and their physicians the information they need to make the best decisions for the full treatment journey. The company currently offers two commercially-available genomic profiling tests, supported by the highest levels of clinical and real world evidence, that provide comprehensive genomic information that can be used to identify the most effective breast cancer treatment possible for each patient.

MammaPrint®, the 70-gene breast cancer recurrence assay, is the only FDA-cleared risk of recurrence test backed by peer-reviewed, prospective outcome data and inclusion in both national and international treatment guidelines. BluePrint®, the 80-gene molecular subtyping assay, is the only commercially-available test that evaluates the underlying biology of a tumor to determine what is driving its growth. Together, MammaPrint® and BluePrint® provide a comprehensive genomic profile to help physicians make more informed decisions in the pre- and post-operative treatment settings.

Agendia develops evidence-based novel genomic tests and forges partnerships with groundbreaking companies to develop next-generation digital treatment tools. The ongoing research builds an arsenal of data that improve patient outcomes and support the evolving clinical needs of patients with breast cancer and their physicians every step of the way, from initial diagnosis to cancer-free.

Agendia’s assays can be ordered on core biopsies or surgical specimens to inform pre- and post-operative treatment decisions. For more information on Agendia’s assays and ongoing trials, please visit www.agendia.com.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Media

Terri Clevenger
Westwicke/ICR Healthcare PR
Tel: 203.856.4326
Terri.Clevenger@icrinc.com

About Business Wire

Business Wire
Business Wire
24 Martin Lane
EC4R 0DR London

+44 20 7626 1982http://www.businesswire.co.uk

(c) 2018 Business Wire, Inc., All rights reserved.

Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Manx Telecom Partners With Mavenir to Transform Its Mobile Voice and Data Network and Trials Open RAN With Mavenir’s Leading Cloud-Native Solutions24.6.2021 10:00:00 CEST | Press release

Mavenir, the Network Software Provider building the future of networks with cloud-native software that runs on any cloud and transforms the way the world connects, announces today that Isle of Man-basedcommunications service provider, Manx Telecom will be using the MAVcore solution to deliver both voice (VoLTE) and data networks (Packet Core). Mavenir will be delivering and deploying an end-to-end solution to Manx Telecom for its On-Island and OV businesses, comprising cloud-native virtualised IMS and Packet Cores. In addition, Manx Telecom will use the MAVair solution to undertake an Open RAN trial. Manx Telecom selected Mavenir as the best fit to meet the company’s overall requirement today and its future architecture needs for IMS, Packet Core and RAN solutions. The MAVcore family includes Mavenir’s global leading VoLTE IMS and voice services delivering VoLTE based virtualised IMS solution including VoLTE roaming and PCRF capability, and its leading-edge Packet Core solution deliver

Philip Morris International: New Study Shows Near-Doubling in Counterfeit Cigarettes in the European Union Drives Increase of Total Illicit Consumption in 202024.6.2021 10:00:00 CEST | Press release

Philip Morris International Inc. (PMI) (NYSE: PM) is calling for public and private representatives to jointly combat illicit trade as a new report produced by KPMG was released on the consumption and flows of illicit cigarettes in 30 European countries—the 27 European Union (EU) member states, as well as U.K., Norway and Switzerland. The study estimates that, while total cigarette consumption continues to decline, the share of illicit cigarettes increased by one half of a percentage point to 7.8% of total consumption in 2020, reaching 34.2 billion cigarettes consumed across the EU 27 member states (EU27). The increase of illicit cigarettes—which consist of contraband, counterfeit, and illicit whites—was driven by an unprecedented 87% surge in counterfeit consumption. The tax loss for governments in the EU27 now amounts to approximately €8.5 billion. The annual study, conducted independently by KPMG and commissioned by PMI, shows how legal and illicit cigarette consumption was impacted

Mavenir and Qualcomm Collaborate to Deliver Open RAN 4G/5G Indoor and Outdoor Radio Solutions for Public and Private Networks24.6.2021 10:00:00 CEST | Press release

Mavenir1, the Network Software Provider building the future of networks with cloud-native software that runs on any cloud and transforms the way the world connects, today announced a collaboration with Qualcomm Technologies, Inc. to develop indoor and outdoor solutions for both private and public network deployments aiming to broaden the choices for Open RAN customers. With rising capacity and coverage demands of 5G, driven by diverse enterprise and consumer requirements, there is a growing need for network densification that harnesses all available spectrum based on flexible and cost-effective radio solutions. This collaboration aims to leverage the power of Mavenir’s software solutions and Qualcomm Technologies’ platform leadership, to deliver a suite of radio solutions based on Open RAN architecture. Mavenir software running on the Qualcomm® 4G and 5G RAN Platforms for Small Cells (FSM), providing a full range of Open RAN software upgradable radio solutions is designed to meet the s

Habu Expands Internationally, Appointing Tim Norris-Wiles as Managing Director EMEA24.6.2021 10:00:00 CEST | Press release

Habu, the Global Innovator in Data Clean Room software, today announced the appointment of industry veteran, Tim Norris-Wiles as the Managing Director of EMEA, as Habu expands internationally and continues to grow its global customer base and business. Building on its tremendous growth in the first half of 2021, Habu’s Data Clean Room software allows brands to benefit from the full value of data in a safe environment, providing measurement, targeting, personalization and access to unique insights for the best marketing results. Through its proprietary methods for cloud data integration and distributed data processing, Habu continues to innovate in ways that enable organizations like Activision, ASICS, Insider and Digital Trends to safely collaborate and fully utilize data within their clean rooms. As the Managing Director of EMEA, Norris-Wiles will oversee Habu’s global growth strategy and execution. He will expand and lead Habu’s international sales organization in Europe and ensure d

Panasonic Announces Signing of Professional Women’s Tennis Player Naomi Osaka as Brand Ambassador24.6.2021 09:48:00 CEST | Press release

Panasonic Corporation has signed a brand ambassador agreement with professional women's tennis player Naomi Osaka. The period of agreement is two years starting from April 22, 2021. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210624005399/en/ Panasonic’s Brand Ambassador Naomi Osaka (Graphic: Business Wire) Panasonic sought the agreement with Ms. Osaka after observing that her values and perspectives on society deeply resonate with its own management philosophy, primarily with regard to the following three points: First, Ms. Osaka takes social issues seriously, looking beyond tennis to share her views on what a better society would look like in her own words. The founder of Panasonic, Konosuke Matsushita, held the notion that a stable state of happiness comes only when both mental stability and material prosperity are secured. Based on this idea, the company endeavors to create an ideal society where all of us can enjoy l

ADVA makes virtual routing simple and affordable with Ensemble SmartWAN24.6.2021 09:00:00 CEST | Press release

ADVA (FSE: ADV) today launched its fully featured Ensemble SmartWAN secure networking solution. Integrated into ADVA’s Ensemble network functions virtualization (NFV) suite, the new technology offers enterprises a simple and affordable way to leverage the core benefits of software-defined WAN (SD-WAN), while removing the need for additional virtual network functions (VNFs). Now businesses can deploy a turnkey solution that delivers dynamic virtual routing, centralized management, and full visibility of network topology. With zero-touch provisioning for easy deployment and temperature-hardened servers, Ensemble SmartWAN significantly improves return on investment for applications such as dynamic and fully meshed networking and smart city services. At the same time, it preserves the benefits of an open system that supports runtime additions of new VNFs or user applications. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210624

Global Banks Preparing to Leverage SWIFT’s New Platform for International Payments Flows24.6.2021 09:00:00 CEST | Press release

Six leading global banks today announced their endorsement for SWIFT’s new transaction management platform and are preparing to use its expanded capabilities to enable new services, improve efficiency and reduce costs when the platform goes live in November 2022. Bank of China, Bank of New York Mellon, BNP Paribas, Citi, Deutsche Bank, and Standard Chartered confirmed their preparations for the platform as the co-operative detailed an ambitious roadmap it will roll out over the next 18 months. New features – including upfront validation of beneficiary details, central management of exceptions, extension of SWIFT’s high-speed gpi rails to lower-value payments and new rich data services based on the ISO 20022 standard – will serve as the building blocks of the enhanced platform. These are integral components of SWIFT’s strategy to facilitate instant and frictionless end-to-end transactions anywhere in the world. The platform evolution builds on extensive work by the SWIFT community in th